Anixa Biosciences Inc (NASDAQ:ANIX) Given Average Recommendation of “Hold” by Analysts

Anixa Biosciences Inc (NASDAQ:ANIX) has been assigned a consensus recommendation of “Hold” from the five research firms that are currently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating on the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $8.50.

ANIX has been the topic of a number of recent analyst reports. HC Wainwright reissued a “buy” rating on shares of Anixa Biosciences in a research report on Friday, June 12th. D. Boral Capital reaffirmed a “buy” rating and set a $10.00 price target on shares of Anixa Biosciences in a research note on Tuesday, June 30th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Anixa Biosciences in a research report on Wednesday, June 17th. Wall Street Zen raised shares of Anixa Biosciences from a “sell” rating to a “hold” rating in a research report on Saturday, June 20th. Finally, Citigroup reaffirmed a “buy” rating on shares of Anixa Biosciences in a research report on Friday, June 12th.

Anixa Biosciences Stock Performance

Shares of ANIX stock opened at $3.06 on Tuesday. The stock has a 50 day moving average of $2.80 and a two-hundred day moving average of $2.90. Anixa Biosciences has a 12 month low of $2.32 and a 12 month high of $5.46. The company has a market capitalization of $104.10 million, a P/E ratio of -9.87 and a beta of 0.59.

Anixa Biosciences (NASDAQ:ANIX) last announced its earnings results on Wednesday, June 10th. The company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.10) by $0.03. Sell-side analysts predict that Anixa Biosciences will post -0.31 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Anixa Biosciences news, CEO Amit Kumar purchased 21,000 shares of the company’s stock in a transaction dated Friday, June 12th. The stock was bought at an average cost of $2.50 per share, for a total transaction of $52,500.00. Following the completion of the transaction, the chief executive officer owned 630,812 shares in the company, valued at approximately $1,577,030. This represents a 3.44% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Insiders have bought 28,836 shares of company stock worth $75,187 over the last 90 days. 26.40% of the stock is currently owned by company insiders.

Institutional Trading of Anixa Biosciences

Hedge funds have recently made changes to their positions in the company. Segall Bryant & Hamill LLC bought a new position in Anixa Biosciences during the first quarter worth $45,000. Renaissance Technologies LLC grew its position in Anixa Biosciences by 13.6% in the 1st quarter. Renaissance Technologies LLC now owns 61,173 shares of the company’s stock worth $158,000 after purchasing an additional 7,300 shares in the last quarter. Kestra Advisory Services LLC increased its position in shares of Anixa Biosciences by 96.2% during the 1st quarter. Kestra Advisory Services LLC now owns 51,000 shares of the company’s stock valued at $132,000 after purchasing an additional 25,000 shares during the last quarter. Virtu Financial LLC purchased a new position in Anixa Biosciences in the fourth quarter valued at approximately $161,000. Finally, Millennium Management LLC bought a new position in Anixa Biosciences during the fourth quarter worth about $38,000. 29.13% of the stock is owned by institutional investors and hedge funds.

Anixa Biosciences Company Profile

Anixa Biosciences is a clinical-stage immuno-oncology and infectious disease company developing novel cell-based immunotherapies and vaccine platforms. Through its Anixa Therapeutics division, the company is advancing antibody and T-cell modalities, including an ovarian cancer immunotherapy candidate and a COVID-19 vaccine leveraging a proprietary virus-like particle (VLP) technology. Its research pipeline emphasizes modular vaccine design and personalized cancer cell therapy aimed at inducing durable immune responses against solid tumors.

In parallel, Anixa Diagnostics is developing the ADAPT diagnostic platform, a high-throughput proteomics approach using engineered peptides derived from spider venom.